Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $121
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Lawrence Biegelsen has maintained an Overweight rating on Abbott Laboratories (NYSE:ABT) and increased the price target from $116 to $121.
December 13, 2023 | 3:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo analyst Lawrence Biegelsen reaffirmed an Overweight rating on Abbott Laboratories and raised the price target to $121.
The reaffirmation of an Overweight rating and an increase in the price target typically signal analyst confidence in the company's future performance, which can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100